Compare Charles River Laboratories Intl. Inc (CRL) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Prospect Capital Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $304.45 (market cap $14.23B), while Prospect Capital Corporation trades at $1.8 (market cap $974.22M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 14.6× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Prospect Capital Corporation for 78 Days on average.
| CRL | PSEC | |
|---|---|---|
Market Cap | $14.23B | $974.22M |
Volume | 1,176,885 | 5,779,996 |
Sector | Health | Financials |
52-Week High | $310.77 | $3.05 |
52-Week Low | $149.93 | $1.82 |
Typical Hold Time | 33 Days | 78 Days |
Enterprise Value | $17.06B | $2.73B |
Dividend Yield | — | 23.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
PSEC trades at $1.84, up 0.55% on the day, with a bearish technical signal from moving averages despite bullish RSI readings. The company reported negative revenue and net income for 2025, though recent quarterly EPS have beaten expectations. Dividend distributions continue, but analyst consensus is mixed with a majority hold rating. Recent news highlights distribution announcements and management commentary on lower middle-market opportunities.
The outlook is cautious; PSEC's high yield and low P/B ratio present value, but persistent negative cash flow, volatile profitability, and a bearish technical trend pose significant risks. Investor sentiment is divided, with concerns over NAV erosion and portfolio contraction offset by income-focused appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
